Altimmune to Present at Upcoming Investor Conferences
On November 10, 2021, Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ALT, announced upcoming presentations by its management team at two significant investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On November 10, 2021, Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ALT, announced upcoming presentations by its management team at two significant investor conferences.
- Stifel’s 2021 Virtual Healthcare Conference: November 15, 2021, at 10:40 am Eastern Time.
- Jefferies London Healthcare Conference: November 18, 2021, at 8:00 am GMT.
Both sessions will be accessible via the Altimmune website.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was +1.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following investor conferences in November 2021:
- Stifel’s 2021 Virtual Healthcare Conference
Monday, November 15, 2021
10:40 am Eastern Time
- Jefferies London Healthcare Conference
Thursday, November 18, 2021
8:00 am GMT
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.